Pharmaceutical company, Glaxo Holding, has developed a new drug called somatript
ID: 3222761 • Letter: P
Question
Pharmaceutical company, Glaxo Holding, has developed a new drug called somatriptan for migrain headaches. Glaxo has made claim that the mean time it takes to enter the bloodsteam is less than 10 min. FDA decided to test of the validity of this claim. and conducted an experiment of randomly selected 30 migraine sufferers. FDA discovered that in the sample of 30, the mean time was 11.0 min. The standard deviation for each measurement is 1 min. (a) What is the null hypothesis and alternative hypothesis for this case? (b) Does FDA accept the null hypothesis or go for alternative?Explanation / Answer
Given that,
population mean(u)=10
sample mean, x =11
standard deviation, s =1
number (n)=30
null, Ho: <10
alternate, H1: >10
level of significance, = 0.05
from standard normal table,right tailed t /2 =1.699
since our test is right-tailed
reject Ho, if to > 1.699
we use test statistic (t) = x-u/(s.d/sqrt(n))
to =11-10/(1/sqrt(30))
to =5.477
| to | =5.477
critical value
the value of |t | with n-1 = 29 d.f is 1.699
we got |to| =5.477 & | t | =1.699
make decision
hence value of | to | > | t | and here we reject Ho
p-value :right tail - Ha : ( p > 5.4772 ) = 0
hence value of p0.05 > 0,here we reject Ho
ANSWERS
---------------
null,the mean time it takes to enter the bloodsteam is less than 10 min, Ho: <10
alternate, H1: >10
test statistic: 5.477
critical value: 1.699
decision: reject Ho
p-value: 0
we don't support the claim that the mean time it takes to enter the bloodsteam
is less than 10 min